Alexandra Czap, MD
Assistant Professor, Department of Neurology, McGovern Medical School at UTHealth Houston
Dr. Alexandra L. Czap is a board-certified neurologist with expertise in vascular neurology.
Dr. Czap received her Bachelor of Science in physiology and neurobiology from the University of Connecticut Honors Program. She graduated from the University of Connecticut School of Medicine and completed neurology residency training at the University of Pittsburgh Medical Center. She completed her fellowship training in vascular neurology at McGovern Medical School at UTHealth.
While at the University of Connecticut, she served as co-principal investigator with Louise McCullough, MD, PhD, a nationally recognized physician-scientist and chair of the Department of Neurology at McGovern Medical School, where she was awarded a T32 Research Training Grant with the National Institute of Neurological Disorders and Stroke. Dr. Czap is the author of numerous peer-reviewed articles in journals such as Stroke, Journal of Neuroinflammation, Journal of Comparative Neurology, Biochemical Pharmacology, and Oncogene, and she has presented her research at national and international conferences.
Her current research interests focus on the natural history and management of cerebrovascular disease and endovascular approaches in cancer.
Dr. Czap is an active member of several societies, including the American Heart Association/American Stroke Association, Society of Vascular and Interventional Neurology, Society for Neuro-Oncology, and the American Academy of Neurology.
Recent News
Endovascular thrombectomy time metrics in the era of COVID-19: observations from the SVIN Multicenter Collaboration
Unprecedented workflow shifts during the coronavirus disease 2019 (COVID-19) pandemic have contributed to delays in acute care delivery, but whether it adversely affected endovascular thrombectomy metrics in acute large vessel occlusion (LVO) is unknown.
Decline in mild stroke presentations and intravenous thrombolysis during the COVID-19 pandemic
To evaluate overall ischemic stroke volumes and rates, specific subtypes, and clinical presentation during the COVID-19 pandemic in a multicenter observational study from eight states across US.
Influence of the COVID-19 Pandemic on Treatment Times for Acute Ischemic Stroke
The pandemic caused by the novel coronavirus disease 2019 (COVID-19) has led to an unprecedented paradigm shift in medical care. We sought to evaluate whether the COVID-19 pandemic may have contributed to delays in acute stroke management at comprehensive stroke centers.
Cerebrovascular events and outcomes in hospitalized patients with COVID-19
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has been associated with a significant risk of thrombotic events in critically ill patients.
Mobile Stroke Unit Computed Tomography Angiography Substantially Shortens Door-to-Puncture Time.
Background and Purpose- Endovascular thrombectomy (ET) door-to-puncture time (DTPT) is a modifiable metric. One of the most important, yet time-consuming steps, is documentation of large vessel occlusion by computed tomography angiography (CTA). We hypothesized that obtaining CTA on board a Mobile Stroke Unit and direct alert of the ET team shortens DTPT by over 30 minutes.